BioSpace News Archive

Earlier this October, Creative Peptides, one of the world’s leading peptide manufacturers, has announced a series of peptide modification services. Now this company makes a further step and releases post-translational modification service.

ARCA biopharma (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that data from the Atrial Fibrillation Burden (AFB) substudy of the Phase 2B GENETIC-AF clinical trial were presented November 11, 2018 in a poster session at the American Heart Association 2018 Scientific Sessions in Chicago.

Rho, a full-service contract research organization (CRO) focused on bringing new products to market through a full range of product development services, today announced that Principal Programmer/Analyst and Statistical Programming Operational Service Lead Kristen Harrington has been appointed to President of SESUG, a Regional Users Group (RUG) for users of SAS® Software.

Alliar - Centro de Imagem Diagnósticos S.A. hereby announces 3Q18 results.

Vapotherm, Inc. announced the pricing of its initial public offering of 4,000,000 shares of common stock at a price to the public of $14.00 per share.

EXPEDITION-8 is the first Phase 3b study evaluating 8 weeks of MAVYRET™ in treatment-naïve chronic hepatitis C virus (HCV)-infected patients with compensated cirrhosis across all major genotypes (GT1-6)1

Interactions with Fc gamma receptors determine efficacy and mechanism-of-action of co-stimulatory checkpoint antibodies

NX Prenatal Inc. announced today that expanding applications of its proprietary NeXosome® liquid biopsy platform were presented at recent scientific conferences.

Specialists shape agenda for combating overuse and misuse of antimicrobials

Personalized Medicine therapy options can drive better outcomes, Slyngshot Health seeks to make these options more accessible through a first-of-its-kind digital network.